Physician profile
Esther Morrison
NPI 1972629392
$3,761.68
in general payments reported to CMS, 2019-2025
18 companies · $365 in 2025
The $365 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.69 · 2020: $113 · 2021: $68.51 · 2022: $916 · 2023: $1,147 · 2024: $1,079 · 2025: $365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,501 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,501.05 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $939.01 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Viiv Healthcare Company | $821.17 | 2022-2025 | Dovato, Rukobia |
| Melinta Therapeutics, LLC | $370.30 | 2022-2024 | Kimyrsa, Rezzayo, Vabomere |
| Astellas Pharma US INC | $351.06 | 2023-2024 | Cresemba |
| Janssen Biotech, INC. | $338.47 | 2022-2023 | Symtuza |
| Gilead Sciences, INC. | $279.99 | 2023-2025 | |
| Insmed, INC. | $144.74 | 2022-2023 | Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.57 | 2023-2025 | Ofev, Jardiance |
| Janssen Products, Lp | $99.00 | 2022 | |
| Abbvie INC. | $81.76 | 2020 | |
| Shionogi INC | $59.70 | 2023-2024 | Fetroja |
| United Therapeutics Corporation | $28.98 | 2024 | Tyvaso |
| Tetraphase Pharmaceuticals, INC. | $27.05 | 2019 | |
| Theratechnologies INC. | $26.66 | 2021-2023 | Egrifta, Trogarzo |
| Napo Pharmaceuticals INC | $23.36 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $23.07 | 2024 | Nuzyra |
| Invivyd INC | $21.14 | 2025 | Pemgarda |
| Philips North America LLC | $18.65 | 2024 | (Ak6) Vest Therapy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Esther Morrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.